Edgard Graner

Prof. Edgard Graner


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Cancer Cell
Verified
Journal Article
Closed access
EGEdgard Graner
Edgard Graner
DTDan Tang
Dan Tang
SRSabrina Rossi
Sabrina Rossi
ABAntonella Baron
Antonella Baron
TMToshiro Migita
Toshiro Migita
MLMassimo F. Loda
Massimo F. Loda

1 March 2000 in Molecular Brain Research
Verified
Journal Article
Closed access
EGEdgard Graner
Edgard Graner
AMAdriana F Mercadante
Adriana F Mercadante
SZSilvio M Zanata
Silvio M Zanata
OFOrestes V Forlenza
Orestes V Forlenza
ACAna L.B Cabral
Ana L.B Cabral
RBRicardo R Brentani
Ricardo R Brentani

1 December 1997 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
VMVilma R. Martins
Vilma R. Martins
EGEdgard Graner
Edgard Graner
JGJosé Garcia-Abreu
José Garcia-Abreu
SSSandro J. De Souza
Sandro J. De Souza
AMAdriana F. Mercadante
Adriana F. Mercadante
RBRicardo R. Brentani
Ricardo R. Brentani

1 May 2006 in Journal of Periodontology
Verified
Journal Article
Closed access
Ricardo D. ColettaRicardo D. Coletta
Ricardo D. Coletta
EGEdgard Graner
Edgard Graner
Generalized gingival enlargement can be caused by a variety of etiological factors. It can be inherited (hereditary gingival fibromatosis [HGF]); associated with other diseases characterizing a syndrome; or induced as a side effect of systemic drugs, such as phenytoin, cyclosporin, or nifedipine. HGF, previously known as elephantiasis gingivae, hereditary gingival hyperplasia, and hypertrophic gingiva, is a genetic disorder characterized by a progressive enlargement of the gingiva. This review will focus on diagnosis, treatment, and control of HGF. The pattern of inheritance, the histopathologic characteristics, and the known biologic and genetic features associated with HGF are also emphasized.

21 August 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DBDebajit K. Biswas
Debajit K. Biswas
SDSun-Chun Dai
Sun-Chun Dai
ACAntonio Cruz
Antonio Cruz
BWBarbara Weiser
Barbara Weiser
EGEdgard Graner
Edgard Graner
APArthur B. Pardee
Arthur B. Pardee
The effect of a kinase inhibitor Go6796 on growth of epidermal growth factor (EGF)-stimulated estrogen receptor negative (ER−) breast cancer cells in vivo and role of nuclear factor kappa B (NF-κB) on tumorogenesis have been investigated. This was studied in an animal model by implanting ER− mouse mammary epithelial tumor cells (CSMLO) in syngeneic A-J mice. ( i ) Local administration of Go6976 an inhibitor of protein kinases C alpha and beta inhibited growth of tumors and caused extensive necrotic degeneration and regression of the tumors without causing any microscopically detectable damage to the vital organs liver and lung. ( ii ) Stable expression of dominant-negative mutants of the beta subunit (dnIkkβ) of the inhibitory kappa B (IκB) kinase (dnIkk) that selectively blocked activation of NF-κB caused loss of tumorigenic potential of CSMLO cells. Stable expression of dnIkkβ also blocked phorbol 12-myristate 13-acetate (PMA)-induced activation of NF-κB and overexpression of cyclin D1, concomitantly with the loss or reduced tumorigenic potential of these cells. Thus, results from in vivo and in vitro experiments strongly suggest the involvement of NF-κB in ER− mammary epithelial cell-mediated tumorigenesis. We propose that blocking NF-κB activation not only inhibits cell proliferation, but also antagonizes the antiapoptotic role of this transcription factor in ER− breast cancer cells. Thus, NF-κB is a potential target for therapy of EGFR family receptor-overexpressing ER− breast cancers.

3 September 2008 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MCMarco A. Carvalho
Marco A. Carvalho
KZKarina G. Zecchin
Karina G. Zecchin
FSFabiana Seguin
Fabiana Seguin
DBDébora C. Bastos
Débora C. Bastos
MAMichelle Agostini
Michelle Agostini
EGEdgard Graner
Edgard Graner
Fatty acid synthase (FASN) is the enzyme responsible for the endogenous synthesis of the saturated fatty acid palmitate. In contrast to most normal cells, malignant cells depend on FASN activity for growth and survival. In fact, FASN is overexpressed in a variety of human cancers including cutaneous melanoma, in which its levels of expression are associated with a poor prognosis and depth of invasion. Here, we show that the specific inhibition of FASN activity by the antiobesity drug Orlistat or siRNA is able to significantly reduce proliferation and promote apoptosis in the mouse metastatic melanoma cell line B16‐F10. These results prompted us to verify the effect of FASN inhibition on the metastatic process in a model of spontaneous melanoma metastasis, in which B16‐F10 cells injected in the peritoneal cavity of C57BL/6 mice metastasize to the mediastinal lymph nodes. We observed that mice treated with Orlistat 48 hr after the inoculation of B16‐F10 cells exhibited a 52% reduction in the number of mediastinal lymph node metastases, in comparison with the control animals. These results suggest that FASN activity is essential for B16‐F10 melanoma cell proliferation and survival while its inactivation by Orlistat significantly reduces their metastatic spread. The chemical inhibition of FASN activity could have a potential benefit in association with the current chemotherapy for melanoma.